Humanized monoclonal antibody (mAb)

Cat.No.	Name	Information
M10890	Spartalizumab	Spartalizumab (anti-PD-1) is a human-derived IgG4 antibody against PD-1 that inhibits the binding of PD-L1 and PD-L2 to PD-1. PDR001 binds to PD-1 with high affinity to inhibit its biological activity; MW: 145.8 KD.
M10603	Anti-human CD28 mAb	CD28 molecule exists on the surface of most T cells and is considered to be a specific surface molecule of T cells. The responsiveness of T cells to antigens is mainly mediated by the CD3/TCR complex, but it also depends on the cooperation of other molecules on the surface of T cells.
M10111	Anti-human CD3 mAb	CD3 is an important marker of T cells, it is composed of five polypeptide chains: γ, δ, ε, ζ, and η.
M9416	Durvalumab	Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.
M9236	Ranibizumab	Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A.
M8984	Denosumab	Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption.
M6224	Etanercept	Etanercept is a dimer fusion protein that binds tumor necrosis factor (TNF) as a TNF inhibitor. Etanercept competitively inhibits the binding of TNF-α and TNF-β to TNF receptors on the cell surface, rendering tumor necrosis factor biologically inactive.
M6223	Tocilizumab	Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
M6222	Adalimumab	Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD.
M6221	Pertuzumab	Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
M6219	Rituximab	Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.
M6218	Trastuzumab	Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
M6166	Bevacizumab	Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody that is an inhibitor of VEGF. It binds to, and neutralizes, all human-derived VEGF-A isoforms (and biologically active protein hydrolysis fragments).MW:149 KD.
M6104	Ipilimumab	Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
M6103	Cetuximab	Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice).
M6102	Pembrolizumab	Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required).
M6101	Atezolizumab	Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. MW: 145 KD. atezolizumab reacts with murine PD-L1 (for human and non-humanized mice).
M6100	Nivolumab	Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice).
M3849	Aflibercept	Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization.
M3847	Alemtuzumab	Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible.
M3835	Alirocumab	Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia.
M3814	Sarilumab	Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting the IL-6-mediated signaling.
M3813	Avelumab (MSB0010718C)	Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1
M1629	Ramucirumab	Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).
M1622	Secukinumab	Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
M1621	Ustekinumab	Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases.
M1618	Vedolizumab	Vedolizumab is a humanized monoclonal antibody that specifically antagonizes Integrin (α4β7) and inhibits the binding of α4β7 to the intestinal mucosal cell adhesion molecule MADCAM-1. Vedolizumab is indicated for humanized mice.
M1616	Daratumumab	Daratumumab (Daratumumab) is a first-in-class, specific anti-CD38 monoclonal antibody (IgG1). (for human or immunodeficient mice).
M1615	Obinutuzumab	Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20.
M1598	Eculizumab	Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.
M1595	Evolocumab	Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
M1545	Infliximab	Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice.
M1539	Omalizumab	Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) and to membrane-bound form of IgE (mIgE).
M1527	Ofatumumab	Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation.
M1519	Matuzumab	Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR.
M1512	Nimotuzumab	Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR.
M1503	Panitumumab	Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR).

Catalog

Signaling Pathways

Product Type

Humanized monoclonal antibody (mAb)

Get to Know Us

Customer Support

Resources

Contact Us